Use of High Resolution Colonic Manometry in Studying Motility
NCT02574611 is a phase 1 interventional trial sponsored by James J. Peters Veterans Affairs Medical Center. As of 21 Nov 2026, it was withdrawn. It studies Glycopyrronium and Neostigmine in Gastrointestinal Dysfunction. The registry lists an enrollment of 0 participants at 1 site in 1 country. The registry lists a start date of 13 Oct 2015 and a primary completion date of 25 Dec 2017.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02574611 |
| Status | Withdrawn |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | James J. Peters Veterans Affairs Medical Center |
| Enrollment | 0 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Gastrointestinal Dysfunction |
| Drugs | Glycopyrronium and Neostigmine |
| Start | 13 Oct 2015 |
| Primary completion | 25 Dec 2017 |
| Study completion | 25 Dec 2018 |
| Last update posted | 28 Sept 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Mark Korsten, MD
James J. Peters Veterans Affairs Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- James J. Peters Va Medical Center
The Bronx
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02574611
Each answer restates registry values shown on this page.
What is NCT02574611?
NCT02574611 is a phase 1 interventional trial sponsored by James J. Peters Veterans Affairs Medical Center. It studies Glycopyrronium and Neostigmine in Gastrointestinal Dysfunction.
Who leads NCT02574611?
The registry names Mark Korsten, MD (principal investigator, James J. Peters Veterans Affairs Medical Center) as the overall official.
Where does NCT02574611 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02574611 study?
The registered drug and biological interventions are Glycopyrronium and Neostigmine.
When did NCT02574611 end?
The registry lists a primary completion date of 25 Dec 2017 and a study completion date of 25 Dec 2018. The sponsor last updated the record on 28 Sept 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.